# High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

> **NCT01124734** · PHASE2 · COMPLETED · sponsor: **Milton S. Hershey Medical Center** · enrollment: 17 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Interleukin-2
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01124734
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2017-07-18
- **Final completion:** 2018-07-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2019-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01124734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01124734, "High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01124734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*